Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are an important class of therapeutics, incorporate a heterocyclic core in their molecular structure and are used for the alleviation of pain and inflammation associated with several pathological conditions. NSAIDs exert anti-inflammatory effects by inhibiting cyclooxygenase enzymes (COXs) which, are useful in the synthesis of prostanoids generated from arachidonic acid. Selective COX-II inhibitors, compared to nonselective inhibitors exhibit reduced gastrointestinal, ulceration and renal side effects. In general, COX-II inhibitors incorporate a five or six-membered heterocyclic motif with built-in sulfonamide or methylsulfonate moiety. Celecoxib, a selective COX-II inhibitor drug, commercialized by Pfizer is applied in the treatment of rheumatoid arthritis, osteoarthritis, and painful menstruation related symptoms. The current review provides a discussion on the methodologies used to construct celecoxib/celebrex® and structural analogs.
Keywords: Celecoxib, Celebrex®, Pyrazoles, Heterocycles, COX, Cycloadditions, Couplings, and Condensations
Current Organic Chemistry
Title:Synthesis of Celecoxib and Structural Analogs- A Review
Volume: 16 Issue: 11
Author(s): Sureshbabu Dadiboyena and Ashton T. Hamme II
Affiliation:
Keywords: Celecoxib, Celebrex®, Pyrazoles, Heterocycles, COX, Cycloadditions, Couplings, and Condensations
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are an important class of therapeutics, incorporate a heterocyclic core in their molecular structure and are used for the alleviation of pain and inflammation associated with several pathological conditions. NSAIDs exert anti-inflammatory effects by inhibiting cyclooxygenase enzymes (COXs) which, are useful in the synthesis of prostanoids generated from arachidonic acid. Selective COX-II inhibitors, compared to nonselective inhibitors exhibit reduced gastrointestinal, ulceration and renal side effects. In general, COX-II inhibitors incorporate a five or six-membered heterocyclic motif with built-in sulfonamide or methylsulfonate moiety. Celecoxib, a selective COX-II inhibitor drug, commercialized by Pfizer is applied in the treatment of rheumatoid arthritis, osteoarthritis, and painful menstruation related symptoms. The current review provides a discussion on the methodologies used to construct celecoxib/celebrex® and structural analogs.
Export Options
About this article
Cite this article as:
Dadiboyena Sureshbabu and T. Hamme II Ashton, Synthesis of Celecoxib and Structural Analogs- A Review, Current Organic Chemistry 2012; 16 (11) . https://dx.doi.org/10.2174/138527212800672664
DOI https://dx.doi.org/10.2174/138527212800672664 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
Call for Papers in Thematic Issues
Catalytic C-H bond activation as a tool for functionalization of heterocycles
The major topic is the functionalization of heterocycles through catalyzed C-H bond activation. The strategies based on C-H activation not only provide straightforward formation of C-C or C-X bonds but, more importantly, allow for the avoidance of pre-functionalization of one or two of the cross-coupling partners. The beneficial impact of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting TNF-Alpha in HIV-1 Infection
Current Drug Targets Microtubule-Stabilizing Natural Products as Promising Cancer Therapeutics
Current Medicinal Chemistry Searching for Artemisinin Production Improvement in Plants and Microorganisms
Current Pharmaceutical Biotechnology Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists
Current Medicinal Chemistry Aptamers and New Bioreceptors for the Electrochemical Detection of Biomarkers Expressed in Hepatocellular Carcinoma
Current Medicinal Chemistry Free Fatty Acids-Sensing G Protein-Coupled Receptors in Drug Targeting and Therapeutics
Current Medicinal Chemistry Prodrugs of Non-steroidal Anti-inflammatory Drugs (NSAIDs): A Long March Towards Synthesis of Safer NSAIDs
Mini-Reviews in Medicinal Chemistry γ-AApeptides as a New Strategy for Therapeutic Development
Current Medicinal Chemistry SNAP-Tag Technology: A Powerful Tool for Site Specific Conjugation of Therapeutic and Imaging Agents
Current Pharmaceutical Design Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Discovery of Potential Sorbitol Dehydrogenase Inhibitors from Virtual Screening
Medicinal Chemistry Biological Effects, Total Phenolic Content and Flavonoid Concentrations of Fragrant Yellow Onion (Allium flavum L.)
Medicinal Chemistry The Beneficial Effects of QIAPI 1<sup>®</sup> against Pentavalent Arsenic-Induced Lung Toxicity: A Hypothetical Model for SARS CoV2-I nduced Lung Toxicity
Current Pharmaceutical Biotechnology Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Carcinogenesis and Diabetic Wound Healing: Evidences of Parallelism
Current Diabetes Reviews Synthesis, Biological Evaluation and Molecular Docking Studies of Novel Di-hydropyridine Analogs as Potent Antioxidants
Current Topics in Medicinal Chemistry Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Metastasis-Associated Protein S100A4: Spotlight on its Role in Cell Migration
Current Cancer Drug Targets Immunotoxins and Neuropeptide-Toxin Conjugates Experimental Applications
Mini-Reviews in Medicinal Chemistry